We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CALAVI

News List

Calquence fails to prevent respiratory failure in COVID-19 patients europeanpharmaceuticalreview
November 16, 2020
AstraZenaca reveals Calquence (acalabrutinib) did not increase the proportion of hospitalised COVID-19 patients who remained alive and free of respiratory failure.
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients worldpharmanews
June 08, 2020
Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19 disease.(1)
AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 worldpharmanews
April 15, 2020
AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.